Can-Fite BioPharma Stock Forecast, Price & News

+0.09 (+4.09 %)
(As of 06/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume861,159 shs
Average Volume2.34 million shs
Market Capitalization$39.37 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Can-Fite BioPharma logo

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.39 out of 5 stars

Medical Sector

748th out of 2,106 stocks

Pharmaceutical Preparations Industry

372nd out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Can-Fite BioPharma (NYSEAMERICAN:CANF) Frequently Asked Questions

Is Can-Fite BioPharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Can-Fite BioPharma stock.
View analyst ratings for Can-Fite BioPharma
or view top-rated stocks.

What stocks does MarketBeat like better than Can-Fite BioPharma?

Wall Street analysts have given Can-Fite BioPharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Can-Fite BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Can-Fite BioPharma?

Can-Fite BioPharma saw a decline in short interest during the month of May. As of May 28th, there was short interest totaling 300,500 shares, a decline of 35.4% from the May 13th total of 465,300 shares. Based on an average daily trading volume, of 3,190,000 shares, the days-to-cover ratio is currently 0.1 days.
View Can-Fite BioPharma's Short Interest

When is Can-Fite BioPharma's next earnings date?

Can-Fite BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, August 26th 2021.
View our earnings forecast for Can-Fite BioPharma

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) issued its quarterly earnings results on Thursday, May, 27th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.05. The biotechnology company earned $0.15 million during the quarter, compared to analyst estimates of $0.30 million. Can-Fite BioPharma had a negative trailing twelve-month return on equity of 150.45% and a negative net margin of 1,680.08%.
View Can-Fite BioPharma's earnings history

How has Can-Fite BioPharma's stock price been impacted by Coronavirus (COVID-19)?

Can-Fite BioPharma's stock was trading at $1.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CANF shares have increased by 50.7% and is now trading at $2.29.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CANF?

3 Wall Street analysts have issued 1 year price objectives for Can-Fite BioPharma's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Can-Fite BioPharma's share price to reach $5.00 in the next year. This suggests a possible upside of 118.3% from the stock's current price.
View analysts' price targets for Can-Fite BioPharma
or view top-rated stocks among Wall Street analysts.

Who are Can-Fite BioPharma's key executives?

Can-Fite BioPharma's management team includes the following people:
  • Prof. Pnina Fishman, Scientific Founder, CEO & Director (Age 73, Pay $598k)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 57, Pay $415k)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 49, Pay $286k)
  • Dr. Ilan Cohn, Co-Founder & Chairman (Age 67)
  • Dr. Vibeke Strand FACR, M.D., FACP, FACR (USA), Sr. Clinical Advisor

Who are some of Can-Fite BioPharma's key competitors?

What other stocks do shareholders of Can-Fite BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Can-Fite BioPharma investors own include OPKO Health (OPK), Advanced Micro Devices (AMD), BioLineRx (BLRX), Genocea Biosciences (GNCA), Arbutus Biopharma (ABUS), Biocept (BIOC), Pfizer (PFE), Protalix BioTherapeutics (PLX), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Can-Fite BioPharma's stock symbol?

Can-Fite BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

Who are Can-Fite BioPharma's major shareholders?

Can-Fite BioPharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (0.46%), Citadel Advisors LLC (0.35%), Citadel Advisors LLC (0.35%), Virtu Financial LLC (0.27%), Stifel Financial Corp (0.07%) and XTX Topco Ltd (0.07%).

Which institutional investors are selling Can-Fite BioPharma stock?

CANF stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.

Which institutional investors are buying Can-Fite BioPharma stock?

CANF stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Citadel Advisors LLC, Citadel Advisors LLC, Stifel Financial Corp, XTX Topco Ltd, and Jane Street Group LLC.

How do I buy shares of Can-Fite BioPharma?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Can-Fite BioPharma's stock price today?

One share of CANF stock can currently be purchased for approximately $2.29.

How much money does Can-Fite BioPharma make?

Can-Fite BioPharma has a market capitalization of $39.37 million and generates $760,000.00 in revenue each year. The biotechnology company earns $-14,440,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Can-Fite BioPharma have?

Can-Fite BioPharma employs 8 workers across the globe.

What is Can-Fite BioPharma's official website?

The official website for Can-Fite BioPharma is www.canfite.co.il.

Where are Can-Fite BioPharma's headquarters?

Can-Fite BioPharma is headquartered at 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel.

How can I contact Can-Fite BioPharma?

Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114 or via email at [email protected]

This page was last updated on 6/25/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.